Significance of anticardiolipin antibodies on short and long term allograft survival and function following kidney transplantation

American Journal of Transplantation

Volumn 4, Issue 11, 2004, Pages 1786-1791

  Forman, John P ^a,b,c   Lin, Julie ^a,c   Pascual, Manuel ^b,c   Denton, Mark D ^b,c   Tolkoff Rubin, Nina ^b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Anticardiolipin antibodies; Kidney transplantation; Outcomes

Indexed keywords

ANTICOAGULANT AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CARDIOLIPIN ANTIBODY; CREATININE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; WARFARIN;

ADULT; AGED; ALLOGRAFT; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTICOAGULATION; ARTICLE; COMPOSITE GRAFT; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; ANTIBODIES, ANTICARDIOLIPIN; ANTIPHOSPHOLIPID SYNDROME; BIOLOGICAL MARKERS; COHORT STUDIES; CREATININE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; TISSUE DONORS;

EID: 7244257721     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1600-6143.2004.00602.x     Document Type: Article

References (24)

1. Hocher B, Slowinski T, Hauser I et al. Association of factor V Leiden mutation with delayed graft function, acute rejection episodes and long-term graft dysfunction in kidney transplant recipients. Thromb Haemost 2001; 87: 194-198.
2. Heidenreich S, Junker R, Wolters H et al. Outcome of kidney transplantation in patients with inherited thrombophilia: Data of a prospective study. J Am Soc Nephrol 2003; 14: 234-239.
3. Fischereder M, Schneeberger H, Lohse P, Kramer BK, Schlondorff D, Land W. Increased rate of renal transplant failure in patients with the G20210A mutation of the prothrombin gene. Am J Kidney Dis 2001; 38: 1061-1064.
4. Nzerue CM, Hewan-Lowe K, Pierangeli S, Harris EN. "Black swan in the kidney": Renal involvement in the antiphospholipid antibody syndrome. Kidney Int 2002; 62: 733-744.
5. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346: 752-763.
6. Joseph RE, Radhakrishnan J, Appel GB. Antiphospholipid antibody syndrome and renal disease. Curr Opin Nephrol Hypertens 2001; 10: 175-181.
7. Ducloux D, Pellet E, Fournier V et al. Prevalence and clinical significance of antiphospholipid antibodies in renal transplant recipients. Transplantation 1999; 67: 90-93.
8. Dalekos GN, Zachou K, Liaskos C. The antiphospholipid syndrome and infection. Curr Rheumatol Rep 2001; 3: 277-285.
9. Harada M, Fujisawa Y, Sakisaka S et al. High prevalence of anticardiolipin antibodies in hepatitis C virus infection: Lack of effects on thrombocytopenia and thrombotic complications. J Gastroenterol 2000; 35: 272-277.
10. Prakash R, Miller CC, III, Suki WN. Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis. Am J Kidney Dis 1995; 26: 347-352.
11. Manns BJ, Burgess ED, Parsons HG, Schaefer JP, Hyndman ME, Scott-Douglas NW. Hyperhomocysteinemia, anticardiolipin antibody status, and risk for vascular access thrombosis in hemodialysis patients. Kidney Int 1999; 55: 315-320.
12. Radhakrishnan J, Williams GS, Appel GB, Cohen DJ. Renal transplantation in anticardiolipin antibody-positive lupus erythematosus patients. Am J Kidney Dis 1994; 23: 286-289.
13. Stone JH, Amend WJ, Criswell LA. Antiphospholipid antibody syndrome in renal transplantation: Occurrence of clinical events in 96 consecutive patients with systemic lupus erythematosus. Am J Kidney Dis 1999; 34: 1040-1047.
14. Vaidya S, Wang CC, Gugliuzza C, Fish JC. Relative risk of post-transplant renal thrombosis in patients with antiphospholipid antibodies. Clin Transplant 1998; 12: 439-444.
15. Vaidya S, Sellers R, Kimball P et al. Frequency, potential risk and therapeutic intervention in end-stage renal disease patients with antiphospholipid antibody syndrome: A multicenter study. Transplantation 2000; 69: 1348-1352.
16. Wagenknecht DR, Becker DG, LeFor WM, McIntyre JA. Antiphospholipid antibodies are a risk factor for early renal allograft failure. Transplantation 1999; 68: 241-246.
17. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum 1999; 42: 1309-1311.
18. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
19. Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria - An addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714.
20. Goerdt PJ, Heim-Duthoy KL, Macres M, Swan SK. Predictive performance of renal function estimate equations in renal allografts. Br J Clin Pharmacol 1997; 44: 261-265.
21. Scientific Registry of Transplant Recipients Staff. Annual Report 2002. SRTR Website. http://www.ustransplant.org/annual.html. Accessed June 20, 2003.
22. Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311-318.
23. Cecka JM. The UNOS renal transplant registry. Clin Transpl 2001; 17: 1-18.
24. Hardy S, Lee SH, Terasaki Pl. Sensitization 2001. Clin Transpl 2001; 17: 271-278.